Supplementary Table S6 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
Year: 2026
Type: supplementary-materials
Abstract: Summary of AZD8701-related adverse events observed in patients treated with AZD8701 + durvalumab
Authors: Lillian L. Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez, Guillermo de Velasco, Eduardo Castanon Alvarez, Christos E. Kyriakopoulos, Melissa Johnson, Kaïssa Ouali, Stephen McMorn, Helen K. Angell, Felicia Ng, Shashank Saran, Mahdiye Bayat, Teresa Collins, Archana Roy, Arthur W. Lambert, Song Cho, Neil Miller, Michele Petruzzelli, John Stone, Christophe Massard
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7165040000
Cites:
Cited by:
Related to: